Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1994 2
1995 3
1996 3
1997 8
1998 7
1999 5
2000 6
2001 17
2002 17
2003 14
2004 11
2005 13
2006 24
2007 33
2008 25
2009 23
2010 23
2011 21
2012 19
2013 25
2014 20
2015 26
2016 26
2017 12
2018 11
2019 17
2020 9
2021 16
2022 9
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17195697

408 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months.
Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-Del-Rí M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Collard A, Boutriau D, Schuerman L, Jacquet JM; Spanish DTPa-HBV-IPV-097 Study Group. Tejedor JC, et al. Pediatr Infect Dis J. 2007 Jan;26(1):1-7. doi: 10.1097/01.inf.0000247070.60063.09. Pediatr Infect Dis J. 2007. PMID: 17195697 Clinical Trial.
Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L; Spanish DTaP-HBV-IPV-097 Study Group. Tejedor JC, et al. Pediatr Infect Dis J. 2006 Aug;25(8):713-20. doi: 10.1097/01.inf.0000227725.61495.c4. Pediatr Infect Dis J. 2006. PMID: 16874171 Clinical Trial.
A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. Vesikari T, et al. Pediatr Infect Dis J. 2013 May;32(5):521-9. doi: 10.1097/INF.0b013e31827e22e3. Pediatr Infect Dis J. 2013. PMID: 23190785 Clinical Trial.
Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
Tejedor JC, Omeñaca F, García-Sicilia J, Verdaguer J, Van Esso D, Esporrín C, Molina V, Muro M, Marés J, Enrubia M, Moraga F, García-Corbeira P, Dobbelaere K, Schuerman L; Spanish DTPa-HBV-IPV/Hib-076 Study Group. Tejedor JC, et al. Pediatr Infect Dis J. 2004 Dec;23(12):1109-15. Pediatr Infect Dis J. 2004. PMID: 15626947 Clinical Trial.
Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F, Arístegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J, Merino JM, Muro Brussi M, Sánchez-Tamayo T, Castro Fernandez J, Cabanillas L, Peddiraju K, Mesaros N, Miller JM. Omeñaca F, et al. Pediatr Infect Dis J. 2011 Nov;30(11):e216-24. doi: 10.1097/INF.0b013e3182293a82. Pediatr Infect Dis J. 2011. PMID: 21747321 Clinical Trial.
The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D. Gatchalian S, et al. Int J Infect Dis. 2008 May;12(3):278-88. doi: 10.1016/j.ijid.2007.08.007. Epub 2007 Nov 5. Int J Infect Dis. 2008. PMID: 17981067 Free article. Clinical Trial.
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L. Wysocki J, et al. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609. Pediatr Infect Dis J. 2009. PMID: 19325450 Clinical Trial.
Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Habermehl P, et al. Hum Vaccin. 2010 Aug;6(8):640-51. doi: 10.4161/hv.6.8.12154. Hum Vaccin. 2010. PMID: 20697200 Clinical Trial.
408 results